Casarini, Ignacio
2 papers on CoChatORCID 0000-0002-0479-9417
Most cited papers
- Verified
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 2,298
- Verified
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
Felip, E., Rojas, C. I., Schenker, M., Kowalski, D. M., Casarini, I. A., Csöszi, T., Şendur, M. A. N., Martins, J., Calles Blanco, A., Wang, C.-C., et al. (2025) · Annals of Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 40
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free